MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

BACKGROUND: MET amplification and MET exon 14 alterations (METex14) in lung cancers impart sensitivity to MET kinase inhibitors. Fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), and IHC, have been used to evaluate MET dependency. Here, we determined the association of MET...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Thorac Oncol
Autores principales: Guo, Robin, Berry, Lynne D., Aisner, Dara L., Sheren, Jamie, Boyle, Theresa, Bunn, Paul A., Johnson, Bruce E., Kwiatkowski, David J., Drilon, Alexander, Sholl, Lynette M., Kris, Mark G.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6708730/
https://ncbi.nlm.nih.gov/pubmed/31228623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.06.009
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares